Time to taper: why 39 percent reduced their ADHD medication in a 41-participant 6-week observational record

Key takeaways

• The real clinical value of non-medication ADHD support is less about replacing medication and more about earning time to taper the dose.
• In a 41-participant 6-week observational record at Sid Ryu Child and Adolescent Psychiatry Clinic, 26 children were on ADHD medication. 10 of those 26 (39 percent) reduced their dose during the 6 weeks. 16 maintained the same dose. No dose increase was reported.
• The K-ARS change was larger in children whose baseline scores were higher (more severe symptoms). Overall mean change (n=38, the subset with full 6-week K-ARS follow-up) was -2.37 (66 percent improved). In the subgroup aged 13 or younger with baseline K-ARS over 13, excluding refractory cases, mean change was -3.80 (79 percent improved).

Hello, this is Dr. Sid Ryu, a child and adolescent psychiatrist.

Over 20 years in the clinic, one of the most common questions I have received is this.

"If we use a non-medication support device, can we stop the medication?"

The answer is not as simple as parents hope. Medication is still the first-line standard treatment for ADHD with adequate clinical evidence. The question itself is not wrong. The shape of the question simply needs a small adjustment. Not "can we stop the medication" but "can we buy enough time to reduce the medication dose."

This piece reframes the 2023 41-participant 6-week K-ARS observational record (with K-ARS change measured in 38 of the 41) from a parent's perspective. Not in the tone of a clinical paper, but in the tone I use to explain this to parents in the clinic.

41 children analyzed, 6 weeks, what did the K-ARS scores actually do

First, the simple numbers.

K-ARS (Korean ADHD Rating Scales) is an 18-item parent-completed instrument that scores inattention, hyperactivity, and impulsivity behaviors observed at home and school. Higher scores indicate more frequent or more severe ADHD symptoms.

Our clinic recruited 54 children and analyzed 41. K-ARS change over 6 weeks could be tracked in 38 of them. Mean values across subgroups looked like this.

At first read, an overall mean change of -2.37 may not feel clinically large. Two interesting patterns sit behind that average.

Finding 1: 39 percent of medicated children reduced their dose

Of the 41 children analyzed, 26 (63 percent) were also on ADHD medication (most often the methylphenidate class: Concerta, Medikinet, and similar agents). In this group, here is what happened to the medication over 6 weeks.

• Dose reduced: 10 (39%)
• Same dose maintained: 16 (61%)
• No dose increase reported

The key here is not "the non-medication support let them stop the medication." The point is that for 39 percent of medicated children, the prescribing clinician judged that a dose reduction was clinically appropriate. Two clinical implications follow.

First, families earned time at a lower side-effect burden. With stimulants such as Concerta or Medikinet, lower doses typically come with reduced appetite suppression, sleep disturbance, and irritability. Behind the "can we stop the medication" question is usually a side-effect concern. A dose reduction alone addresses part of that concern.

Second, the side-effect recovery pattern in the dose-reduction group is clinically meaningful. One of the key findings Dr. Sid Ryu records from this study reads as follows: in children who had been on high-dose methylphenidate, when the dose was reduced after starting SmartDream as an adjunct, attention was maintained without the common side effects of appetite loss or low energy. In addition, in the group that kept the same dose while using SmartDream alongside, parents frequently reported "study focus improved" (an additive effect). In other words, the clinical value of non-medication support is not in replacing the medication, but in working alongside it: either reducing the side-effect burden, or reinforcing the medication effect.

Finding 2: children with more severe symptoms showed larger changes

The overall mean change was -2.37 (66 percent improved). Subgroups defined by higher baseline K-ARS scores showed larger changes.

In age 13 and under with baseline K-ARS over 13 (moderate or above), the mean change was -3.10 (67 percent improved). After excluding refractory cases (children who needed several medication adjustments during the 6 weeks), the figure becomes -3.80 (79 percent improved).

The intuition parents often bring into the clinic ("My child is too severe, medication is the only option") runs counter to the pattern in this data. Children with more severe baseline scores showed larger non-medication-support effects in this sample. This is a mean. Individual response varies.

Limits I want to state plainly

This is not a clinical paper. It is a single-clinician open-trial observational record. The limits are explicit.

• No control group. Without a non-SmartDream comparison arm, some portion of the change can be explained by natural progression, observer effects, or shifts in the treatment environment.
• Parent-reported scale. K-ARS is filled out by parents. Parental expectation (placebo) cannot be fully excluded.
• Clinic-bound sample. Participants are patients of Sid Ryu Child and Adolescent Psychiatry Clinic. Generalization to the broader population has limits.
• Not a randomized controlled trial. The U.S. Monarch eTNS in the same category has a separate FDA-registered RCT. The conclusions are not interchangeable with this observational record.

So this data does not place SmartDream as an ADHD treatment. The claim is not "ADHD can be treated without medication." It is "when a non-medication adjunct joined the clinical pathway of children already receiving medication, this is the pattern that was observed."

What I tell parents in the clinic

The most accurate expectation for non-medication ADHD support is this.

• Not to stop medication, but to support the clinical state where the dose can be reduced.
• To lower side-effect burden so the family can sustain the treatment pathway longer.
• More clinical meaning for children whose medication effect is weak, or whose dose cannot be titrated up due to side effects.

Parents considering non-medication support are encouraged to first clarify these three expectations with the prescribing clinician. Please do not stop ADHD medication on your own judgment.

SmartDream is not a medical device. It is not intended to diagnose, treat, or prevent any disease. ADHD diagnosis and treatment must be discussed with a child and adolescent psychiatrist.